Browse Volumes & Issues

Reactions Weekly

All Volumes & Issues

Volume 1719, Issue 1, September 2018

September 15, 2018

ISSN: 0114-9954 (Print) 1179-2051 (Online)

In this issue (239 articles)

News item

Recent Product Monograph updates in Canada

Page 1
News item

Risk of serious rare infection with SGLT2 inhibitors

Page 2
Clinical study

ACTZ vs mannitol for cisplatin-induced nephrotoxicity

Page 3
Clinical study

ADR data via social media compared with standard sources

Page 4
Clinical study

Bleomycin: low-risk therapy for good-risk testicular cancer

Page 5
Clinical study

Diclofenac linked with risk of major adverse CV events

Page 6
Review

Disproportionality analysis reveals new AEs for levonorgestrel

Page 7
Clinical study

Drug utilisation in pregnant women in Burkina Faso analysed

Page 8
Clinical study

Infection-related costs higher with dasatinib than nilotinib

Page 9
Clinical study

No increased risk of dementia/AD with long-term PPIs

Page 10
Clinical study

Point-of-care renal function test saves AE-related costs

Page 11
Clinical study

Rivaroxaban: no reduction in death rate or increase in major bleeding

Page 12
Case report

Abatacept

Page 13
Case report

Acenocoumarol overdose

Page 14
Case report

Acenocoumarol/enoxaparin sodium

Page 15
Case report

Adalimumab

Page 16
Case report

Adalimumab

Page 17
Case report

Afatinib

Page 18
Case report

Aldesleukin

Page 19
Case report

Alemtuzumab/fingolimod/methylprednisolone

Page 20

Continue reading...

To view the rest of this content please follow the download PDF link above.